[HTML][HTML] Clinical implications of monitoring nivolumab immunokinetics in non–small cell lung cancer patients
…, Y Yano, S Yokota, Y Kinehara, Y Naito, T Otsuka… - JCI insight, 2018 - ncbi.nlm.nih.gov
BACKGROUND. The PD-1–blocking antibody nivolumab persists in patients several weeks
after the last infusion. However, no study has systematically evaluated the maximum …
after the last infusion. However, no study has systematically evaluated the maximum …
[HTML][HTML] Association of advanced glycation end products with sarcopenia and frailty in chronic kidney disease
…, T Matsui, H Yuichiro, T Kadoguchi, T Otsuka… - Scientific reports, 2020 - nature.com
Prevalence of sarcopenia is high in patients with chronic kidney disease (CKD), especially
in those with dialysis. Various pathological conditions related to CKD, such as chronic …
in those with dialysis. Various pathological conditions related to CKD, such as chronic …
Phase2 study of bevacizumab with carboplatin–paclitaxel for non-small cell lung cancer with malignant pleural effusion
…, T Yamadori, K Nakao, K Asami, T Yasue, T Otsuka… - Medical oncology, 2013 - Springer
Vascular endothelial growth factor (VEGF) is involved in non-small cell lung cancer (NSCLC)
with malignant pleural effusion (MPE), but little is known regarding the efficacy of …
with malignant pleural effusion (MPE), but little is known regarding the efficacy of …
Febuxostat for treating allopurinol-resistant hyperuricemia in patients with chronic kidney disease
Y Sakai, T Otsuka, D Ohno, T Murasawa, N Sato… - Renal failure, 2014 - Taylor & Francis
Background: Availability of the novel xanthine oxidase inhibitor febuxostat, which has multiple
excretion pathways, enables investigation of the significance of serum uric acid control on …
excretion pathways, enables investigation of the significance of serum uric acid control on …
[HTML][HTML] CpG ODN (K3)—toll-like receptor 9 agonist—induces Th1-type immune response and enhances cytotoxic activity in advanced lung cancer patients: a phase I …
T Otsuka, S Nishida, T Shibahara, B Temizoz… - BMC cancer, 2022 - Springer
Background Cytosine-phosphate-guanine oligodeoxynucleotide (CpG ODN) (K3)—a novel
synthetic single-stranded DNA immune adjuvant for cancer immunotherapy—induces a …
synthetic single-stranded DNA immune adjuvant for cancer immunotherapy—induces a …
[HTML][HTML] Efficacy and safety of Infliximab for steroid‑resistant immune‑related adverse events: A retrospective study
…, Y Nakai, S Yamamoto, T Otsuka… - Molecular and …, 2021 - spandidos-publications.com
The present study investigated outcomes of infliximab (IFX) treatment among 8 Japanese
patients with various types of cancer (4 with malignant melanoma, 3 with lung cancer and 1 …
patients with various types of cancer (4 with malignant melanoma, 3 with lung cancer and 1 …
[HTML][HTML] Rapid intracranial response to osimertinib, without radiotherapy, in nonsmall cell lung cancer patients harboring the EGFR T790M mutation: two case reports
…, H Hirata, Y Naito, M Hamaguchi, T Otsuka… - Medicine, 2017 - journals.lww.com
Rationale: Most of nonsmall cell lung cancer (NSCLC) patients harboring epidermal growth
factor receptor (EGFR) activating mutations eventually acquire resistance to the first EGFR-…
factor receptor (EGFR) activating mutations eventually acquire resistance to the first EGFR-…
Predictive significance of body composition indices in patients with head and neck squamous cell carcinoma treated with nivolumab: A multicenter retrospective study
Y Takenaka, N Takemoto, T Otsuka, M Nishio… - Oral Oncology, 2022 - Elsevier
Background The identification of predictive factors is imperative for identifying patients with
optimal responses to nivolumab. We aimed to determine whether body composition …
optimal responses to nivolumab. We aimed to determine whether body composition …
Effectiveness of tyrosine kinase inhibitors in Japanese patients with non-small cell lung cancer harboring minor epidermal growth factor receptor mutations: results …
T Otsuka, M Mori, Y Yano, J Uchida… - Anticancer …, 2015 - ar.iiarjournals.org
Aim: Non-small cell lung cancer (NSCLC) with minor mutations in the epidermal growth factor
receptor (EGFR) gene, except for the common 15 base-pair deletions in exon 19 and the …
receptor (EGFR) gene, except for the common 15 base-pair deletions in exon 19 and the …
Efficacy and safety of mycophenolate mofetil in treating immune‐related hepatitis induced by immune checkpoint inhibitor use: A retrospective study
…, M Takagi, T Inoue, S Ohe, Y Nakai, T Otsuka… - JGH …, 2023 - Wiley Online Library
Background and Aim To investigate the outcomes in eight Japanese patients with cancer
treated with mycophenolate mofetil (MMF) and corticosteroids for immune checkpoint inhibitor …
treated with mycophenolate mofetil (MMF) and corticosteroids for immune checkpoint inhibitor …